Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
This product will be manufactured at Lupin’s Pithampur facility in India
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
UTD2 is the world's first oral epothilone microtubule inhibitor
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Subscribe To Our Newsletter & Stay Updated
